Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Prospective, Randomized, Modified Double-Blind, Comparative Trial Assessing the Immunogenicity and Reactogenicity of a Tetanus-Diphtheria 5-Component (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae Types 2 and 3) Acellular Pertussis Vaccine (Tdap) in Healthy Adolescents and Adults.

Next Previous
X
Search
Trial Profile

A Phase III, Prospective, Randomized, Modified Double-Blind, Comparative Trial Assessing the Immunogenicity and Reactogenicity of a Tetanus-Diphtheria 5-Component (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae Types 2 and 3) Acellular Pertussis Vaccine (Tdap) in Healthy Adolescents and Adults.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP vaccine (Primary) ; Diphtheria-tetanus vaccine
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi Pasteur

    • Most Recent Events

    • 05 Apr 2018 New trial record
    • 02 Jun 2005 Results published in the JAMA: the Journal of the American Medical Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top